BioSight
Companies
DBV Technologies S.A. logo

DBVT

NASDAQCHATILLON, I0
DBV Technologies S.A.

DBV Technologies is a late-stage biopharmaceutical company developing Viaskin, a skin patch that delivers allergens through intact skin to train the immune system without triggering bloodstream exposure—an approach designed to treat food allergies safely in children. The company's lead candidate, Viaskin Peanut Patch, has completed five Phase 3 trials for peanut allergy in children ages 4–7, with a regulatory submission planned for the first half of 2026. DBV is also studying the patch in younger toddlers ages 1–3.

Price history not yet available for DBVT.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar